News

Aprazer Healthcare Launched SORAFEKAST

Aprazer Healthcare Launched SORAFEKAST (Sorafenib Tablets ) is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.